[ad_1]
Merck announced on Thursday that the European Commission has approved its Delstrigo, a combination of doravirine, lamivudine and tenofovir disoproxil fumarate, for the treatment of adults with HIV-1 infection.
[ad_2]
Brussels has also given the green light, for the same indication, its Pifeltro in combination with other antiretroviral drugs, authorization valid also for the 28 Member States of the European Union, as well as Iceland, Norway and Lichtenstein .
The US pharmaceutical company recalls that a committee of the European Agency for Medicines has put a positive opinion on these two new products against AIDS last September.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Source link
